B+
Bull case
20%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
GYRE
Gyre TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Hydronidone now has a concrete China regulatory path after priority review and NDA submission, and Cullgen adds pipeline breadth and PRC development capability while Q1 revenue still grew modestly.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cullgen integration and the ongoing portfolio review could distract management and delay capital-allocation payoffs.
Momentum
61
Value
43
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.00 · Bull $11.50 · Bear $3.75Analysis 2026-05-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.67
Why
Momentum61 · Δ7d -
Value43 · Δ7d -0.0
Sentiment56 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Cullgen integration and the ongoing portfolio review could distract management and delay capital-allocation payoffs.
- • ETUARY remains the dominant commercial product, so any softness in the legacy franchise can outweigh early-stage pipeline news.
- • ETUARY remains the commercial anchor and still drove most product revenue, so the business is concentrated in one mature asset while higher operating costs, acquisition integration, and execution risk can offset pipeline optionality.
Catalyst clock
2026-05-04
Cullgen broadens the pipeline, but integration and capital allocation are now central
Lead driver: Sentiment · See AI snapshot
Momentum
61
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
43
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-15.2
Sentiment
56
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 61.2 / Value 43.2 / Sentiment 56.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-29. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.75
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$722.09M
Beta
1.89
Shares Out
106.03M
P/E (TTM)
122.7
P/S (TTM)
6.71
P/FCF (TTM)
533.62
Rev YoY
-2.1%
EPS YoY
+358.1%
Gross Margin
+94.3%
Op Margin
-11.4%
Net Debt
-$51.49M
Current Ratio
4.26
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data